Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177 oxodotreotide injection in somatostatin receptor-positive advanced neuroendocrine neoplasms (non-G1/G2 GEP-NET)
CTR20241283Phase 3Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of dotatate in apudoma (NET), sponsored by Sinotau Pharmaceutical Group. Started Jul 2024; status: active.
02
Drugs
dotatate
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on CTR20241283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241283.